Skip to main content
. Author manuscript; available in PMC: 2010 Mar 27.
Published in final edited form as: Eur J Neurosci. 2005 Aug;22(3):587–594. doi: 10.1111/j.1460-9568.2005.04241.x

Fig. 2.

Fig. 2

Effect of ecto-domain of the rat Nogo-66 receptor (27–310) fused to a rat IgG [NgR(310)ecto-Fc] and methylprednisolone (MP) on functional recovery after spinal cord injury (SCI). (A) BBB score was recorded weekly for 4 weeks. All treatment groups showed improved BBB scores compared with controls over the course of the study. *P < 0.05 vs. control, two-way repeated measure ANOVA with Tukey’s posthoc test. (B) BBB score was significantly improved in MP-treated rats 2 days after SCI. *P < 0.05 vs. control, two-way repeated measure ANOVA with Tukey’s posthoc test. (C) BBB scores normalized to day 2 for individual animals illustrate a significant improvement in functional recovery in NgR(310)ecto-Fc-treated rats ± MP 2, 3 and 4 weeks after SCI. *P < 0.05 vs. control, two-way repeated measure ANOVA with Tukey’s posthoc test. (D) Frequency of consistent plantar stepping and hindlimb–forelimb coordination, illustrating the proportion of rats in each group that attained a score of 14 or higher 3 and 4 weeks after SCI. Unlike control rats, all treated animals were able to walk with hindlimb–forelimb coordination by 4 weeks after injury. Combined treatment with NgR(310)ecto-Fc and MP significantly improved the rate of functional recovery. *P < 0.05 vs. control Fischer exact test. (E) Mean stride length was significantly improved in NgR(310)ecto-Fc- and MP + NgR(310)ecto-Fc-treated groups compared with controls. *P < 0.05, one-way ANOVA with Dunnett’s posthoc test.